STOCKHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring August 30, 2024, for shares of Calliditas Therapeutics AB - CALTPRNewsWire • Friday
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitisPRNewsWire • Friday
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, CALT, SGE on Behalf of ShareholdersGlobeNewsWire • 06/07/24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, CALT on Behalf of ShareholdersAccesswire • 06/06/24
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates Merger and Expiring Tender Offer - AKLI and CALTAccesswire • 06/06/24
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 18, 2024, for shares of Calliditas Therapeutics AB – CALTGlobeNewsWire • 06/05/24
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 18, 2024, for shares of Calliditas Therapeutics AB - CALTPRNewsWire • 06/04/24
Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathyPRNewsWire • 05/30/24
Calliditas Therapeutics Presents Data at the 61st European Renal Association CongressPRNewsWire • 05/28/24
CALT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Calliditas Therapeutics AB Is Fair to ShareholdersBusiness Wire • 05/28/24
Asahi Kasei to Acquire Calliditas Therapeutics AB to Accelerate Growth as a Global Healthcare CompanyBusiness Wire • 05/28/24
Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei CorporationPRNewsWire • 05/28/24
In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of ActionPRNewsWire • 05/16/24
Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in ChinaPRNewsWire • 05/14/24
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibPRNewsWire • 05/06/24